BioQuiddity Enters into an Exclusive License
BioQuiddity has announced the signing of an exclusive license and supply agreement with Sandoz, a division of Novartis.
BioQuiddity Incorporated has announced the signing of an exclusive
license and supply agreement with Sandoz, a division of Novartis, under which
Sandoz has the right to market BioQuiddity’s ready‐to‐use ropivacaine and
propofol infusion pharmaceutical products in the United States. Under the
agreement, BioQuiddity is responsible for obtaining the requisite regulatory
approvals and supplying the unit‐dose infusion systems, and
Sandoz is responsible for marketing and commercializing the products.
“We are thrilled to collaborate with Sandoz, a proven leader in the healthcare industry. Our ready‐to-use drug delivery platform provides a therapy specific solution that is immediately deployable at the point of care without multiple preparation steps,” said Josh Kriesel, President and CEO of BioQuiddity. “We look forward to rapidly offering a portfolio of innovative cost effective infusion solutions in the United States through this collaboration.”
About BioQuiddity Inc.
BioQuiddity is a privately held specialty pharmaceutical company focused on developing and commercializing ready‐to‐use infusible pharmaceuticals. The Company’s infusion platform addresses some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQuiddity’s vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company’s proprietary unit‐dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. West Pharmaceutical Services, an existing strategic partner of BioQuiddity’s, will be assembling the ready‐to‐use infusion systems.